Polycystic Ovary Syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: First group: control: Metformin: 500 mg tablets: 2 tablets per day for three months + (uniformly in all groups: 1200 kcal diet formulated the first month, 1100 kcal second month and 1
with regard to the foods with good nutritional value). Intervention 2: Group 2: First Intervention: Traditional Persian Medicine model: Twenty cupping sessions and each session for fifteen minutes + H
with regard to the foods with good nutritional value). Intervention 3: Group 3: Second Intervention: Electro-Acupuncture model: Using single use acupuncture needles At fixed points
Leaving needles for 30 minutes, 20 times in three months + Metformin: 500 mg Tablets: 2 tablets per day for three months + (uniformly in all groups: 1200 kcal diet formulated the first month, 1100 kca
with regard to the foods with good nutritional value). Intervention 4: Group 4: Third Intervention: Holistic treatment group: Traditional Persian Medicine model: Twenty cupping sessions and each sess
Leaving needles for 30 minutes, 20 times in three months + Metformin: 500 mg tablets: 2 tablets per day for three months + (uniformly in all groups: 1200 kcal diet formulated the first month, 1100 kca
with regard to the foods with good nutritional value).
Treatment - Drugs
First group: control: Metformin: 500 mg tablets: 2 tablets per day for three months + (uniformly in all groups: 1200 kcal diet formulated the first month, 1100 kcal second month and 1000 kcal third m
with regard to the foods with good nutritional value)
Group 2: First Intervention: Traditional Persian Medicine model: Twenty cupping sessions and each session for fifteen minutes + Herbal combination based on Fennel in the form of 2.5 gram granulated sa
Group 3: Second Intervention: Electro-Acupuncture model: Using single use acupuncture needles At fixed points
Group 4: Third Intervention: Holistic treatment group: Traditional Persian Medicine model: Twenty cupping sessions and each session for fifteen minutes + Herbal combination based on Fennel in the for
Sponsors
Vice chancellor for research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 40 Years
Inclusion criteria
Inclusion criteria: The main inclusion criteria of the study: Women with polycystic ovary syndrome whose disease is diagnosed based on a series of clinical symptoms and laboratory; Aged between 15 and 40 years; And their Body Mass Index higher than 25. The main Exclusion criteria of the study: 1: The desire to become pregnant during treatment; 2: Body Mass Index equal to or less than 25; 3: Menopause; 4: Uncontrolled blood pressure; 5: Pregnancy; 6: Smoking; 7: Alcohol consumption; 8: Patients with thyroid disorders: Thyroid-Stimulating Hormone higher or lower than normal; 9: Hyperprolactinemia (Prolactin more than 50); 10: Oral contraceptives, anti-diabetic, anticoagulants, estrogen and antiandrogen drug consumers in the three months prior to the study; 11: Mass in ultrasonography report; 12: The sudden appearance of symptoms such as hirsutism within a short time (suspect to androgen-producing tumors); 13: The higher the Testosterone concentration of 150 Ng per deciliter (probability of androgen producing tumors); 14: Fasting Insulin more than 80 micro units per milliliter (suspect to severe Insulin resistance syndrome); 15: Bleeding disorders; 16: Patients with psychological or biological sexual identity disorder; 17: Patients with severe psychiatric problems leading to hallucinations and delusions and psychosis
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstrual period. Timepoint: Three months before the start of treatment to the end of intervention (three months after the start) each month. Method of measurement: Calculated according to the patient statements.;Body Mass Index. Timepoint: Once a week, beginning and end of treatment (three months after the start). Method of measurement: By (Body Composition Analyzer System) model Gaia 359.;Fasting insulin. Timepoint: Before and three months after intervention. Method of measurement: Fasting serum insulin Concentration in µU/ml.;LH to FSH ratio. Timepoint: Before and three months after intervention. Method of measurement: Serum concentration in MIU/ML.;Polycystic ovary view on ultrasound. Timepoint: Before and three months after intervention. Method of measurement: The increase in the size of the stroma (more than 0.7 to 7.5 mm) or not (on average) more than 12 follicles with a diameter of 2 to 9 mm in both ovaries on ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fast blood sugar. Timepoint: Before and three months after intervention. Method of measurement: Fasting serum sugar concentration in mg/dl.;Fast cholesterol. Timepoint: Before and three months after intervention. Method of measurement: Fasting serum cholesterol concentration in mg/dl.;Serum prolactin. Timepoint: Before and three months after intervention. Method of measurement: Serum prolactin concentration in ng/ml.;Liver enzymes: SGOT and SGPT. Timepoint: Before and three months after intervention. Method of measurement: Serum SGOT and SGPT concentration in U/l.;Waist-to-hip Ratio. Timepoint: Before and three months after intervention. Method of measurement: Manually using anatomical markers in cm. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Rouhani
School of Persian and complementary medicine of Mashhad
Outcome results
None listed